Journal
PHARMACEUTICALS
Volume 14, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/ph14050455
Keywords
triple-negative breast cancer (TNBC); targeted therapy; immunotherapy
Categories
Funding
- Avera Cancer Institute, South Dakota [SD 57105]
Ask authors/readers for more resources
Metastatic triple-negative breast cancer is a unique and complex form of breast cancer with high rates of relapse and distant metastasis. Chemotherapy is crucial for managing this subtype and preventing disease recurrence for long-term survival. New agents such as eribulin, PARP inhibitors, and ADCs targeting TROP2 are approved for the management of this disease.
Metastatic triple-negative breast cancer (TNBC) is a distinct and immensely complex form of breast cancer. Among all subtypes of breast cancers, TNBC has a comparatively high rate of relapse, a high rate of distant metastasis, and poor overall survival after standard chemotherapy. Chemotherapy regimens are an essential component of the management of this estrogen receptor-negative, progesterone receptor-negative, and epidermal growth factor receptor2 negative subtype of breast cancers. Chemotherapy is critical for preventing the recurrence of the disease and for achieving long-term survival. Currently, a couple of agents are approved for the management of this disease, including chemotherapy like eribulin, targeted therapy like PARP inhibitor, as well as an antibody-drug conjugate (ADC) to target TROP2. Like many other metastatic cancers, immune checkpoint inhibitors (ICIs) have also been approved for TNBC patients with PD-L1 positive tumors and high tumor mutational burden. In this review article, we discuss these newly approved and promising novel agents that may change the therapeutic landscape for advanced/metastatic TNBC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available